Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods

Gloria M Reeves, Courtney Keeton, Christoph U Correll, Jacqueline L Johnson, Robert M Hamer, Linmarie Sikich, Lindsey Hazzard, Cheryl Alderman, Abigail Scheer, Micah Mabe, Sandeep Kapoor, Eva Sheridan, Irmgard Borner, Kristin Bussell, Sara Pirmohamed, Terrence C Bethea, Raja Chekuri, Rhoda Gottfried, Shauna P Reinblatt, Erin Santana, Mark A Riddle, Gloria M Reeves, Courtney Keeton, Christoph U Correll, Jacqueline L Johnson, Robert M Hamer, Linmarie Sikich, Lindsey Hazzard, Cheryl Alderman, Abigail Scheer, Micah Mabe, Sandeep Kapoor, Eva Sheridan, Irmgard Borner, Kristin Bussell, Sara Pirmohamed, Terrence C Bethea, Raja Chekuri, Rhoda Gottfried, Shauna P Reinblatt, Erin Santana, Mark A Riddle

Abstract

Background: Youth with serious mental illness may experience improved psychiatric stability with second generation antipsychotic (SGA) medication treatment, but unfortunately may also experience unhealthy weight gain adverse events. Research on weight loss strategies for youth who require ongoing antipsychotic treatment is quite limited. The purpose of this paper is to present the design, methods, and rationale of the Improving Metabolic Parameters in Antipsychotic Child Treatment (IMPACT) study, a federally funded, randomized trial comparing two pharmacologic strategies against a control condition to manage SGA-related weight gain.

Methods: The design and methodology considerations of the IMPACT trial are described and embedded in a description of health risks associated with antipsychotic-related weight gain and the limitations of currently available research.

Results: The IMPACT study is a 4-site, six month, randomized, open-label, clinical trial of overweight/obese youth ages 8-19 years with pediatric schizophrenia-spectrum and bipolar-spectrum disorders, psychotic or non-psychotic major depressive disorder, or irritability associated with autistic disorder. Youth who have experienced clinically significant weight gain during antipsychotic treatment in the past 3 years are randomized to either (1) switch antipsychotic plus healthy lifestyle education (HLE); (2) add metformin plus HLE; or (3) HLE with no medication change. The primary aim is to compare weight change (body mass index z-scores) for each pharmacologic intervention with the control condition. Key secondary assessments include percentage body fat, insulin resistance, lipid profile, psychiatric symptom stability (monitored independently by the pharmacotherapist and a blinded evaluator), and all-cause and specific cause discontinuation. This study is ongoing, and the targeted sample size is 132 youth.

Conclusion: Antipsychotic-related weight gain is an important public health issue for youth requiring ongoing antipsychotic treatment to maintain psychiatric stability. The IMPACT study provides a model for pediatric research on adverse event management using state-of-the art methods. The results of this study will provide needed data on risks and benefits of two pharmacologic interventions that are already being used in pediatric clinical settings but that have not yet been compared directly in randomized trials.

Trial registration: Clinical Trials.gov NCT00806234.

Figures

Figure 1
Figure 1
Screening to randomization flow chart. Note: HLE = Healthy Lifestyle Education.

References

    1. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second generation antipsychotics during first-time use in children and adolescents. JAMA. 2009;302:1763–1771.
    1. Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2010;19:124–137.
    1. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114–126. doi: 10.1038/nrendo.2011.156.
    1. Kuehn BM. Questionable antipsychotic prescribing remains common, despite serious risks. JAMA. 2010;303:1582–1584. doi: 10.1001/jama.2010.453.
    1. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17:97–107. doi: 10.1016/j.molmed.2010.10.010.
    1. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Schulz SC. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. SchizophrBull. 2008;34:60–71.
    1. Sikich L, Hamer RM, Bashford RA, Scheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133–145. doi: 10.1038/sj.npp.1300327.
    1. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21:517–535. doi: 10.1089/cap.2011.0015.
    1. Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother. 2010;10:1175–1200. doi: 10.1586/ern.10.85.
    1. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants and antipsychotics. J Clin Psychiatry. 2011;72:655–670. doi: 10.4088/JCP.11r07064.
    1. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010;12:CD006629.
    1. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35:1520–1530. doi: 10.1038/npp.2010.21.
    1. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140:159–168. doi: 10.1016/j.schres.2012.03.017.
    1. Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69:1046–1056. doi: 10.4088/JCP.v69n0702.
    1. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165:352–358. doi: 10.1176/appi.ajp.2007.07010079.
    1. Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA. Schizophrenia trials network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) Am J Psychiatry. 2011;168:947–956. doi: 10.1176/appi.ajp.2011.10111609.
    1. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents – a follow-up of the Harvard growth study of 1922 to 1935. N Engl J Med. 1992;327:1350–1355. doi: 10.1056/NEJM199211053271904.
    1. Baker JL, Olsen LW, Sørensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med. 2007;357:2329–2337. doi: 10.1056/NEJMoa072515.
    1. Hannon TS, Rao G, Arslanian SA. Childhood obesity and type 2 diabetes mellitus. Pediatrics. 2005;116:473–480. doi: 10.1542/peds.2004-2536.
    1. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346:802–810. doi: 10.1056/NEJMoa012578.
    1. Serdula MK, Ivery D, Coates RJ, Freedman DS, Williamson DF, Byers T. Do obese children become obese adults? a review of the literature. Prev Med. 1993;22:167–177. doi: 10.1006/pmed.1993.1014.
    1. Power C, Lake JK, Cole TJ. Body mass index and height from childhood to adulthood in the 1958 British born cohort. Am J Clin Nutr. 1997;66:1094–1101.
    1. Guo SS, Chumlea WC. Tracking of body mass index in children in relation to overweight in adulthood. Am J Clin Nutr. 1999;70:145S–148S.
    1. Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa heart study. Pediatrics. 2001;108:712–718. doi: 10.1542/peds.108.3.712.
    1. ADA/APA. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–6001.
    1. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771–791. doi: 10.1097/01.chi.0000220851.94392.30.
    1. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:9–20. doi: 10.1097/chi.0b013e31815b5cb1.
    1. Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? Psychiatry Res. 2009;170:172–176. doi: 10.1016/j.psychres.2008.10.007.
    1. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–1431. doi: 10.1176/appi.ajp.2008.08050756.
    1. Molling PA, Lockner AW, Sauls RJ, Eisenberg L. Committed delinquent boys: the impact of perphenazine and of placebo. Arch Gen Psychiatry. 1962;7:70–76. doi: 10.1001/archpsyc.1962.01720010072009.
    1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. doi: 10.1056/NEJMoa051688.
    1. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the ziprasidone observational study of cardiac outcomes (ZODIAC) Am J Psychiatry. 2011;168:193–201. doi: 10.1176/appi.ajp.2010.08040484.
    1. Whitlock EP, O'Connor EA, Williams SB, Beil TL, Lutz KW. Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF. Pediatrics. 2010;125:e396–e418. doi: 10.1542/peds.2009-1955.
    1. Van Mil EG, Westerterp KR, Kester AD, Delemarre-Van De Waal HA, Gerver WJ, Saris WH. The effect of sibutramine on energy expenditure and body composition in obese adolscents. J Clin Endocrinol Metab. 2007;92:1409–1414. doi: 10.1210/jc.2006-0264.
    1. Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entitites approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf. 2011;20:772–777. doi: 10.1002/pds.2155.
    1. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21S:12–23.
    1. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71–77. doi: 10.1016/S0140-6736(07)60033-6.
    1. Rogovik AL, Chanoine JP, Goldman RD. Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity. Drugs. 2010;70:335–346.
    1. Ferraro D, Di Trapani G. Topiramate in the prevention of pediatric migraine: literature review. J Headache Pain. 2008;9:147–150. doi: 10.1007/s10194-008-0030-1.
    1. Ellinger LK, Ipema HJ, Stachnik JM. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. Ann Pharmacother. 2010;44:668–679. doi: 10.1345/aph.1M550.
    1. Kim E, Liu NC, Yu IC, Lin HY, Lee YF, Sparks JD, Chen LM, Chang C. Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes. 2011;60:1493–1503. doi: 10.2337/db10-0393.
    1. Wald AB, Uli NK. Pharmacotherapy in pediatric obesity: current agents and future directions. Rev Endocr Metab Disord. 2009;10:205–214. doi: 10.1007/s11154-009-9111-y.
    1. Brufani C, Fintini D, Nobili V, Patera PI, Cappa M, Brufani M. Use of metformin in pediatric age. Pediatr Diabetes. 2011;12:580–586.
    1. Lee YJ, Jeong JH. A systematic review of metformin to limit weight-gain with atypical antipsychotics. J Clin Pharm Ther. 2011;36:537–545. doi: 10.1111/j.1365-2710.2011.01255.x.
    1. Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25:299–305. doi: 10.1177/0269881109353461.
    1. Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J. 2008;29:1130–1134.
    1. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163:2072–2079. doi: 10.1176/appi.ajp.163.12.2072.
    1. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J. Schizophrenia Patient Outcomes Research Team (PORT) The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010;36:48–70. doi: 10.1093/schbul/sbp115.
    1. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third national health and nutrition examination survey, 1988–1994. Arch Pediatr Adolesc Med. 2003;157:821–827. doi: 10.1001/archpedi.157.8.821.
    1. Leibenluft E, Charney DS, Towbin KE, Bhangoo RK, Pine DS. Defining clinical phenotypes of juvenile mania. Am J Psychiatry. 2003;160:430–437. doi: 10.1176/appi.ajp.160.3.430.
    1. Correll CU. From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(2):S12–S21.
    1. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–2410. doi: 10.1210/jc.85.7.2402.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883.
    1. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–1470. doi: 10.2337/diacare.22.9.1462.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner